
Luc Vanheel has joined the European Medicines Agency (EMA) as the head of its administration division. A Belgian national, Vanheel …

Pfizer has signed a multi-billion dollar deal to develop one of Merck KGaA’s investigational drugs, MSB0010718C, an anti-PD-L1 antibody. The …

Marketing communications group Creston has announced that its Creston Health arm will now be rebranded as Health Unlimited. Under the …

People in the UK believe antibiotic resistance is second only to terrorism among threats to the public, according to a …

The stately dance between Actavis and Allergan has culminated in the former buying the Botox manufacturer in a $66 billion …

Bayer MaterialScience is getting a new head of industrial operations and technology as Dr Tony Van Osselaer retires from the …
Ffyona Dawber has scooped two prestigious Stevie® Awards at the 11th annual Stevie Awards for Women in Business held in …

GlaxoSmithKline is basking in some good news after topping the league table of pharma companies which do the most to …

The US FDA has approved Sanofi’s Lemtrada for multiple sclerosis, almost a year after rejecting the drug on concerns about …

The great physicist Lord Kelvin said: “If you can measure something, and express it in numbers, then you know something …

Epic Sciences has confirmed the appointment of Toni Wayne as the vice president of its human resources department. Wayne has …

The future of Guido Rasi, head of Europe’s drugs regulator, is up in the air after a legal ruling which …

Health secretary Jeremy Hunt has laid out efficiency plans that he hopes will save the NHS up to £10 billion …

Three experimental Ebola therapies will be tested at sites operated by Médecins Sans Frontières (MSF) in West Africa, according to …

The EMA has published a response to European Ombudsman Emily O’Reilly’s questions about some of its trial data redactions. O’Reilly’s …

Hospitals in England are taking an increasing share of the NHS’s bill for drugs approved by NICE, according to a …

Dublin-based speciality pharma firm Actavis which is currently in talks to buy Allergan for $60 billion, has hired a chief …
Plans to improve the quality of patient care by introducing a ‘kitemark’ to safely validate healthcare apps have been announced …

Allergan is attempting to block a recent Valeant hostile takeover bid by seeking the rumoured alternative merger deal with Actavis, …